Insights into immuno-oncology drug development landscape with focus on bone metastasis
Open Access
- 5 July 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1121878
Abstract
Bone is among the main sites of metastasis in breast, prostate and other major cancers. Bone metastases remain incurable causing high mortality, severe skeletal-related effects and decreased quality of life. Despite the success of immunotherapies in oncology, no immunotherapies are approved for bone metastasis and no clear benefit has been observed with approved immunotherapies in treatment of bone metastatic disease. Therefore, it is crucial to consider unique features of tumor microenvironment in bone metastasis when developing novel therapies. The vicious cycle of bone metastasis, referring to crosstalk between tumor and bone cells that enables the tumor cells to grow in the bone microenvironment, is a well-established concept. Very recently, a novel osteoimmuno-oncology (OIO) concept was introduced to the scientific community. OIO emphasizes the significance of interactions between tumor, immune and bone cells in promoting tumor growth in bone metastasis, and it can be used to reveal the most promising targets for bone metastasis. In order to provide an insight into the current immuno-oncology drug development landscape, we used 1stOncology database, a cancer drug development resource to identify novel immunotherapies in preclinical or clinical development for breast and prostate cancer bone metastasis. Based on the database search, 24 immunotherapies were identified in preclinical or clinical development that included evaluation of effects on bone metastasis. This review provides an insight to novel immuno-oncology drug development in the context of bone metastasis. Bone metastases can be approached using different modalities, and tumor microenvironment in bone provides many potential targets for bone metastasis. Noting current increasing interest in the field of OIO, more therapeutic opportunities that primarily target bone metastasis are expected in the future.Keywords
This publication has 82 references indexed in Scilit:
- Tremelimumab: research and clinical developmentOncoTargets and Therapy, 2016
- Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone MetastasesHuman Gene Therapy, 2015
- The Intricate Role of CXCR4 in Cancer2014
- B7-H3 is Overexpressed in Patients Suffering Osteosarcoma and Associated with Tumor Aggressiveness and MetastasisPLOS ONE, 2013
- Stimulation of B7-H3 (CD276) directs the differentiation of human marrow stromal cells to osteoblastsImmunobiology, 2011
- TGF-β in cancer and bone: Implications for treatment of bone metastasesBone, 2011
- Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cellsBlood, 2010
- Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumorsInvestigational New Drugs, 2009
- TalabostatExpert Opinion on Investigational Drugs, 2007
- The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralizationProceedings of the National Academy of Sciences, 2004